BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Digitalage Announces MVP Launch for Live, Creator-First Media Platform

NFL MVP Josh Allen leaves Nike to sign with New Balance

NATIONAL LEAGUE